The MagicTouch sirolimus-coated balloon (SCB), which demonstrated adequate safety and efficacy in treating de novo coronary lesions at 1 year, showed an “excellent” safety and efficacy profile concerning those lesions that resulted in a dissection, a new study sub-analysis shows.